Medical Oncologist
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
Andrea B. Apolo, M.D. is a nationally and internationally recognized expert in bladder cancer research. She graduated summa cum laude from Lehman College, City University of New York, with a Bachelor of Science degree in chemistry and biochemistry. She earned her medical degree at Albert Einstein College of Medicine in New York City. She completed a residency in internal medicine at New York-Presbyterian Hospital/Weill Cornell Medical Center and completed a medical oncology fellowship at Memorial Sloan Kettering Cancer Center, also in New York City. In 2010 she was recruited to the National Cancer Institute’s Physician-Scientist Early Investigator Program to build a translational bladder cancer program. In 2014 Dr. Apolo received the Lasker Clinical Research Scholars Award and in 2021 was granted tenure at the National Institutes of Health.
Dr. Apolo is dedicated to improving the treatment and survival of patients with bladder cancer and other genitourinary tumors. Her research involves developing and designing clinical trials to test novel therapies for bladder, kidney, and rare genitourinary cancers. Her pioneering research has led to FDA approval of avelumab for bladder cancer and cabozantinib/nivolumab combination therapy for kidney cancer.